Biomay Cooperates with BioNTech to Provide DNA Template for COVID-19 mRNA Vaccine

Biomay, a Vienna primarily primarily based biotech producer, this day announced their partnership with BioNTech SE to give a boost to the current chain for manufacturing of the Pfizer-BioNTech COVID-19 mRNA vaccine. Biomay is undoubtedly one of many manufacturers supplying BioNTech with the DNA template for the in-vitro transcription of their mRNA active ingredient.The manufacturing settlement changed into initiated all by the clinical development segment of the vaccine in Q1/2020. In the period in-between, Biomay has grow to be a formally certified vendor for BioNTech. The scope of providers and products entails process and analytical development, adopted by GMP preparation of the cell monetary institution, manufacturing of round DNA plasmid and at last preparation of the linear DNA template.In 2021, Biomay has produced and delivered extra than one batches of released DNA template and supported the mRNA vaccine production thanks to this famous manufacturing bid, and the firm will proceed to enact so all by the year. Hans Huber, Chief Govt Officer of Biomay, is pleased about Biomay cooperating with BioNTech on this globally an famous mission: “Biomay is proud to be making an active contribution to combating the coronavirus pandemic. Our employees are extremely motivated and fully attentive to the predominant responsibility associated with this cooperation. We would esteem to thank BioNTech for their belief in Biomay´s skills. Now we remember been in a establish to prove that our proprietary plasmid manufacturing platform is esteem minded to plan the needed top quality and abundant volume of DNA template.” About the Pfizer-BioNTech COVID-19 VaccineThe Pfizer-BioNTech COVID-19 vaccine, which is in accordance with BioNTech proprietary mRNA skills, changed into developed by each BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder within the European Union, and the holder of emergency spend authorizations or similar in america (jointly with Pfizer), United Kingdom, Canada and other countries prematurely of a deliberate utility for elephantine marketing authorizations in these countries.About BiomayBiomay AG is a biopharmaceutical contract development and manufacturing group (CDMO) with a world reach. Biomay is is called a vendor of plasmid DNA (pDNA), recombinant proteins and mRNA. Biomay´s customers encompass start-ups, midsize biotech companies and multinational enterprises, predominantly from Europe and the US. Beside the manufacturing of active substances and drug merchandise in accordance with standards of Appropriate Manufacturing Be conscious (GMP), the firm offers process and assay development as successfully as manufacturing of microbial cell banks. Biomay is currently developing a truly built-in biotech manufacturing plant in Aspern Seestadt, Vienna. This greenfield investment will exclusively be dedicated to Biomay´s biotech CDMO actions. Parallel manufacturing traces will enable Biomay to make greater its capacities by a bid of 10 with respect to batch scale and bioreactor volumes (rounded up to ~ 1000 L). Biomay will switch to its unique facility in December this year, with GMP operations scheduled to start in Q1/2022. Contact DataDr. Christian Gruber Biomay AG +43-7966296-100 Contact Us
Be taught More